# Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma

> **NCT00561912** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Interferon Alfa-2b

## Key facts

- **NCT ID:** NCT00561912
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low accrual.
- **Last updated:** 2011-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00561912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00561912, "Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00561912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*